Literature DB >> 11517395

Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus.

J R Lokensgard1, S Hu, W Sheng, M vanOijen, D Cox, M C Cheeran, P K Peterson.   

Abstract

Cytokine (TNF-alpha/beta, IL-1beta, IL-6, IL-18, IL-10, and IFN-alpha/beta/gamma) and chemokine (IL-8, IP-10, MCP-1, MIP-1alpha/beta, and RANTES) production during herpes simplex virus (HSV) 1 infection of human brain cells was examined. Primary astrocytes as well as neurons were found to support HSV replication, but neither of these fully permissive cell types produced cytokines or chemokines in response to HSV. In contrast, microglia did not support extensive viral replication; however, ICP4 was detected by immunochemical staining, demonstrating these cells were infected. Late viral protein (nucleocapsid antigen) was detected in <10% of infected microglial cells. Microglia responded to nonpermissive viral infection by producing considerable amounts of TNF-alpha, IL-1beta, IP-10, and RANTES, together with smaller amounts of IL-6, IL-8, and MIP-1alpha as detected by RPA and ELISA. Surprisingly, no interferons (alpha, beta, or gamma) were detected in response to viral infection. Pretreatment of fully permissive astrocytes with TNF-alpha prior to infection with HSV was found to dramatically inhibit replication, resulting in a 14-fold reduction of viral titer. In contrast, pretreatment of astrocytes with IL-1beta had little effect on viral replication. When added to neuronal cultures, exogenous TNF-alpha or IL-1beta did not suppress subsequent HSV replication. Exogenously added IP-10 inhibited HSV replication in neurons (with a 32-fold reduction in viral titer), however, similar IP-10 treatment did not affect viral replication in astrocytes. These results suggest that IP-10 possesses direct antiviral activity in neurons and support a role for microglia in both antiviral defense of the brain as well as amplification of immune responses during neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517395     DOI: 10.1080/13550280152403254

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  42 in total

1.  Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome.

Authors:  N McGrath; N E Anderson; M C Croxson; K F Powell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

2.  Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1.

Authors:  C Shimeld; J L Whiteland; N A Williams; D L Easty; T J Hill
Journal:  J Gen Virol       Date:  1997-12       Impact factor: 3.891

3.  Cytokines and other markers of intrathecal immune response in patients with herpes simplex encephalitis.

Authors:  E Aurelius; B Andersson; M Forsgren; B Sköldenberg; O Strannegård
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

4.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

5.  Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis.

Authors:  B Wildemann; K Ehrhart; B Storch-Hagenlocher; U Meyding-Lamadé; S Steinvorth; W Hacke; J Haas
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus.

Authors:  E Feduchi; M A Alonso; L Carrasco
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

7.  Interaction of herpes simplex virus with mononuclear phagocytes is dependent on the differentiation stage of the cells.

Authors:  T Bruun; A K Kristoffersen; H Rollag; M Degré
Journal:  APMIS       Date:  1998-02       Impact factor: 3.205

8.  Correlation of virus replication, cytokine (TNF-alpha and IL-1) producing cells, neuronal necrosis and inflammation after intranasal infection of mice with herpes simplex virus strains of different virulence.

Authors:  I Walev; H P Dienes; J Bohl; J Podlech; D Falke
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection.

Authors:  Y H Su; X T Yan; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1.

Authors:  C Shimeld; J L Whiteland; S M Nicholls; E Grinfeld; D L Easty; H Gao; T J Hill
Journal:  J Neuroimmunol       Date:  1995-08       Impact factor: 3.478

View more
  73 in total

1.  Corilagin Protects Against HSV1 Encephalitis Through Inhibiting the TLR2 Signaling Pathways In Vivo and In Vitro.

Authors:  Yuan-Jin Guo; Tao Luo; Fei Wu; Huan Liu; Hua-Rong Li; Yuan-Wu Mei; Shu-Ling Zhang; Jun-Yan Tao; Ji-Hua Dong; Yuan Fang; Lei Zhao
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

Review 2.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 3.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

4.  The growth compromised HSV-2 mutant DeltaRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippocampal cultures.

Authors:  Michael D Gober; Jennifer M Laing; Scott M Thompson; Laure Aurelian
Journal:  Brain Res       Date:  2006-10-03       Impact factor: 3.252

5.  Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons.

Authors:  Jieliang Li; Shuxian Hu; Lin Zhou; Li Ye; Xu Wang; Jie Ho; Wenzhe Ho
Journal:  Glia       Date:  2010-09-27       Impact factor: 7.452

Review 6.  Toll-like receptors in defense and damage of the central nervous system.

Authors:  Rajagopal N Aravalli; Phillip K Peterson; James R Lokensgard
Journal:  J Neuroimmune Pharmacol       Date:  2007-04-03       Impact factor: 4.147

7.  Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis.

Authors:  Robyn S Klein; Eugene Lin; Bo Zhang; Andrew D Luster; Judy Tollett; Melanie A Samuel; Michael Engle; Michael S Diamond
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Microglia are the major cellular source of inducible nitric oxide synthase during experimental herpes encephalitis.

Authors:  Cristina P Marques; Maxim C-J Cheeran; Joseph M Palmquist; Shuxian Hu; James R Lokensgard
Journal:  J Neurovirol       Date:  2008-05       Impact factor: 2.643

Review 9.  Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis.

Authors:  Hui Liu; Ke Qiu; Qiang He; Qiang Lei; Wei Lu
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-19       Impact factor: 4.147

10.  Microglia-induced IL-6 protects against neuronal loss following HSV-1 infection of neural progenitor cells.

Authors:  Ana J Chucair-Elliott; Christopher Conrady; Min Zheng; Chandra M Kroll; Thomas E Lane; Daniel J J Carr
Journal:  Glia       Date:  2014-05-07       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.